Analysis of the therapeutic effect of Wuzhuyu decoction combined with dolasetron mesylate in the treatment of chemotherapy-induced vomiting

doi:10.11958/20252748

Abstract

Abstract:

Objective To investigate the effect of evodia delavonium decoction combined with dolasetron mesylate on the efficacy in patients of chemotherapy-induced vomiting. Methods A total of 116 patients with chemotherapy-induced vomiting admitted to our hospital from June 2023 to January 2025 were enrolled. Patients were divided into two groups with 58 cases in each group. The control group was treated with dolasetron mesylate for antiemetic, and the observation group was supplemented with evodia decoction on the basis of it. The treatment effects including complete remission rate and complete control rate of patients in the acute stage, delayed period and whole course of treatment were counted, and the degree of vomiting after treatment was evaluated. Serotonin (5-HT), immune function indicators, and liver and kidney function indicators before and after treatment were evaluated. Results Compared with the control group, the observation group showed an increased complete relief rate and complete control rate during the delayed phase and throughout the treatment (P<0.05). There was significant difference in the degree of vomiting between the two groups (P<0.05). Compared with the control group, 5-HT levels decreased in the delayed phase of the observation group (P<0.05). Compared with the control group, the levels of immunoglobulin A, immunoglobulin M and immunoglobulin G increased after treatment in the observation group (P<0.05). There were no significant differences in blood urea nitrogen, creatinine, alanine aminotransferase and aspartate aminotransferase before and after treatment between both groups (P>0.05), and there were no significant differences in these indicators between the two groups (P>0.05). Conclusion Wuzhuyu decoction combined with dexamethasone can effectively relieve chemotherapy-induced vomiting, reduce the severity of vomiting and 5-HT levels, improve humoral immunity, and is safe and effective.

Key words: antineoplastic combined chemotherapy protocols, vomiting, Wu Zhu Yu Tang, dolasetron mesylate

CLC Number:

R730.53

Figures/Tables 6

References 20

[1]	YAN Y, LÓPEZ-ALCALDE J, ZHANG L, et al. Acupuncture for the prevention of chemotherapy-induced nausea and vomiting in cancer patients: a systematic review and meta-analysis[J]. Cancer Med, 2023, 12(11):12504-12517. doi:10.1002/cam4.5962.
[2]	NEEFJES E C W,VAN DER VORST M J D L. Nausea and vomiting after chemotherapy:an ongoing problem for patients[J]. Ned Tijdschr Geneeskd, 2023, 10(167):D7477.
[3]	PATEL P, ROBINSON P D, WAHIB N, et al. Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients:a systematic review and meta-analysis[J]. Support Care Cancer, 2022, 30(11):8855-8869. doi:10.1007/s00520-022-07287-w.
[4]	PATEL P, ROBINSON P D, COHEN M, et al. Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients:a clinical practice guideline[J]. Pediatr Blood Cancer, 2022, 69(12):e30001. doi:10.1002/pbc.30001.
[5]	THEODOSOPOULOU P, REKATSINA M, STAIKOU C. The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting:the role of pharmacogenetics[J]. Minerva Anestesiol, 2023, 89(6):565-576. doi:10.23736/S0375-9393.22.16983-X.
[6]	ZHAO Y, HE M, LIANG R, et al. Evaluation of antiemetic therapy for hepatic arterial infusion chemotherapy with oxaliplatin,fluorouracil,and leucovorin[J]. Ther Clin Risk Manag, 2021, 17:73-77. doi:10.2147/TCRM.S283192.
[7]	李冬梅, 孔菲, 姜洪娟, 等. 耳穴压豆治疗老年肺癌患者多日化疗所致恶心呕吐的效果评价[J]. 军事护理, 2025, 42(2):5-9.
	LI D M, KONG F, JIANG H J, et al. Study on the effect of auricular point compression therapy on chemotherapy induced nausea and vomiting in elderly lung cancer patients[J]. Military Nursing, 2025, 42(2):5-9. doi:10.3969/j.issn.2097-1826.2025.02.002.
[8]	天津市抗癌协会癌症康复与姑息治疗专业委员会, 天津市医师协会肿瘤多学科诊疗专业委员会. 难治性化疗相关性恶心呕吐防治的天津专家共识(2025版)[J]. 天津医药, 2025, 53(1):1-8.
	Tianjin Anti-Cancer Association Committee of Rehabilitation and Palliative Care, Tianjin Medical Doctor Association Committee of Tumor Multidisciplinary Diagnosis and Treatment. Tianjin expert consensus on the prevention and treatment of refractory chemotherapy-related nausea and vomiting (2025 edition)[J]. Tianjin Med J, 2025, 53(1):1-8. doi:10.11958/20240783.
[9]	FREITES-MARTINEZ A, SANTANA N, ARIAS-SANTIAGO S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr(Engl Ed), 2021, 112(1):90-92. doi:10.1016/j.ad.2019.05.009.
[10]	RAJABALIZADEH R, GHASEMZADEH RAHBARDAR M, HOSSEINZADEH H. Medicinal herbs in treating chemotherapy-induced nausea and vomiting:a review[J]. Phytother Res, 2022, 36(10):3691-3708. doi:10.1002/ptr.7563.
[11]	张金璐. 半夏厚朴汤合吴茱萸汤治疗肝胃不和型反流性食管炎的临床观察[D]. 河北: 承德医学院, 2023.
	ZHANG J L. Clinical observation on the treatment of reflux esophagitis of the liver and stomach disharmony type with Banxia Houpu Decoction combined with Wu Zhu Yu Decoction[D]. Hebei: Chengde Medical College, 2023.
[12]	杨坤, 甘丽华, 郭超峰. 吴茱萸汤治疗呕吐的方证关系研究[J]. 西部中医药, 2024, 37(5):97-100.
	YANG K, GAN L H, GUO C F. Study on the formulae-syndrome relationship in the treatment of vomiting by Wuzhuyu Tang[J]. Western Journal of Traditional Chinese Medicine, 2024, 37(5):97-100. doi:10.12174/j.issn.2096-9600.2024.05.18.
[13]	ZHOU Z, ZHOU Y, ZHANG Z, et al. Progress on the effects and underlying mechanisms of evodiamine in digestive system diseases,and its toxicity:a systematic review and meta-analysis[J]. Phytomedicine, 2024, 132:155851. doi:10.1016/j.phymed.2024.155851.
[14]	SUN Q, XIE L, SONG J, et al. Evodiamine:a review of its pharmacology,toxicity,pharmacokinetics and preparation researches[J]. J Ethnopharmacol, 2020, 262:113164. doi:10.1016/j.jep.2020.113164.
[15]	CHOI J, LEE J, KIM K, et al. Effects of ginger intake on chemotherapy-induced nausea and vomiting:a systematic review of randomized clinical trials[J]. Nutrients, 2022, 14(23):4982. doi:10.3390/nu14234982.
[16]	HARDI H, ESTUWORO G K, LOUISA M. Effectivity of oral ginger supplementation for chemotherapy induced nausea and vomiting (CINV) in children:a systematic review of clinical trials[J]. J Ayurveda Integr Med, 2024, 15(4):100957. doi:10.1016/j.jaim.2024.100957.
[17]	IRVING H, TUREK I, KETTLE C, et al. Tapping into 5-HT3 receptors to modify metabolic and immune responses[J]. Int J Mol Sci, 2021, 22(21):11910. doi:10.3390/ijms222111910.
[18]	LIN L, LIU Y, TANG R, et al. Evodiamine:a extremely potential drug development candidate of alkaloids from evodia rutaecarpa[J]. Int J Nanomedicine, 2024, 19:9843-9870. doi:10.2147/IJN.S459510.
[19]	夏青青, 陈偶英, 曾勇, 等. 吴茱萸汤研究热点及趋势可视化分析[J]. 中国中医药信息杂志, 2024, 31(2):84-89.
	XIA Q Q, CHEN O Y, ZENG Y, et al. Visual analysis on research hotspots and trends of Wuzhuyu Decoction[J]. Chinese Journal of Information on Traditional Chinese Medicine, 2024, 31(2):84-89. doi:10.19879/j.cnki.1005-5304.202303152.
[20]	贾宁, 李杨, 唐艳萍. 吴茱萸汤之方证探析[J]. 中国中西医结合外科杂志, 2023, 29(4):541-543.
	JIA N, LI Y, TANG Y P. Analysis of prescription and symptoms of Wu Zhu Yu Decoction[J]. Chinese Journal of Surgery of Integrated Traditional and Western Medicine, 2023, 29(4):541-543. doi:10.3969/j.issn.1007-6948.2023.00.024.

组别		性别				年龄/岁
组别		男		女		年龄/岁
对照组		11（18.97）		47（81.03）		51.45±6.87
观察组		9（15.52）		49（84.48）		53.02±7.25
χ²或t		0.242				1.196
组别	肿瘤类型				TNM分期
组别	肺癌		乳腺癌		Ⅱ期		Ⅲ期
对照组	25（43.10）		33（56.90）		22（37.93）		36（62.07）
观察组	28（48.28）		30（51.71）		26（44.83）		32（55.17）
χ²或t	0.313				0.569

组别		性别				年龄/岁
组别		男		女		年龄/岁
对照组		11（18.97）		47（81.03）		51.45±6.87
观察组		9（15.52）		49（84.48）		53.02±7.25
χ²或t		0.242				1.196
组别	肿瘤类型				TNM分期
组别	肺癌		乳腺癌		Ⅱ期		Ⅲ期
对照组	25（43.10）		33（56.90）		22（37.93）		36（62.07）
观察组	28（48.28）		30（51.71）		26（44.83）		32（55.17）
χ²或t	0.313				0.569

组别	完全缓解
组别	急性期	延迟期	全程
对照组	36（62.07）	34（58.62）	30（51.72）
观察组	43（71.14）	48（82.76）	37（63.79）
χ²	1.945	8.155^＊＊	1.731
组别	完全控制
组别	急性期	延迟期	全程
对照组	28（48.28）	26（44.83）	17（29.31）
观察组	38（65.52）	45（77.59）	33（56.90）
χ²	3.515	13.107^＊＊	8.999^＊＊

组别	完全缓解
组别	急性期	延迟期	全程
对照组	36（62.07）	34（58.62）	30（51.72）
观察组	43（71.14）	48（82.76）	37（63.79）
χ²	1.945	8.155^＊＊	1.731
组别	完全控制
组别	急性期	延迟期	全程
对照组	28（48.28）	26（44.83）	17（29.31）
观察组	38（65.52）	45（77.59）	33（56.90）
χ²	3.515	13.107^＊＊	8.999^＊＊

组别	0级	Ⅰ级	Ⅱ级	Ⅲ级
对照组	34（58.62）	14（24.14）	7（12.07）	3（3.45）
观察组	47（81.03）	7（12.07）	3（5.17）	1（1.72）
Z	2.631^＊＊